BACKGROUND: @entity1 and young @entity1 (CYP) with @entity4932 ( @entity4932 ) are known to have impaired health-related quality of life (HRQoL), which is improved significantly for many by treatment with @entity1499 ( @entity6822 ). However, a significant proportion of CYP experience difficulties in taking @entity6822 , which may reduce its potential benefits for HRQoL. The aim of this research was to examine how CYP with @entity4932 perceive @entity6822 treatment and how this relates to HRQoL. METHODS: CYP aged 8-16 years taking @entity6822 for @entity4932 completed an adapted Parent Adherence Report Questionnaire, which contains 100  mm visual analogue scales, to assess difficulty taking @entity6822 , adherence, frequency of negative reactions and helpfulness of @entity6822 . They also completed the Pediatric Quality of Life Inventory (PedsQL) Generic and Rheumatology scales. We collected data on age, gender, @entity4932 course, disease duration, @entity6822 duration of use, route and dose. Number of inflamed and limited joints were indicators of disease severity. RESULTS: One hundred sixteen CYP participated. Most considered @entity6822 helpful (median 87; interquartile range (IQR) 50.75-98) and reported adherence was high (median 98; IQR 90-100). There was greater variability on scores for difficulty (median 22; IQR 2-69) and frequency of negative reactions (median 14.5; IQR 1.25-80). Mean (S.D.) scores on the PedsQL Physical and Psychosocial subscales were 71.63 (24.02) and 71.78 (19.59) respectively, indicating poorer HRQoL than that reported by healthy @entity1 . After controlling for demographic and disease variables, poorer physical HRQoL was significantly accounted for by greater difficulty in taking @entity6822 . Poorer psychosocial HRQoL was significantly accounted for by subcutaneous @entity6822 administration, a lower rating of @entity6822 helpfulness and a greater reported difficulty in taking @entity6822 . CONCLUSIONS: Taking @entity6822 for @entity4932 was viewed as helpful by most CYP but HRQoL was poorer in those who reported greater difficulty in taking @entity6822 .

The experience of taking XXXX for @entity4932 : results of a cross-sectional survey with @entity1 and young @entity1 .

@entity1 :: ('9606', 'Species') :: ['children', 'Children', 'people'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity4932 :: ('MESH:D001171', 'Disease') :: ['JIA', 'juvenile idiopathic arthritis']
@entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']
